Hilden, Germany; Germantown, Maryland; and Chicago, Illinois, May 31, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with Freenome, a leading artificial intelligence (AI) genomics company, to accelerate the development and commercialization of next-generation sequencing (NGS) tests to enable precision medicine in cancer treatment. The alliance is part of... Read more
● Introduces pipeline to reach patients more quickly with next-generation sequencing for cancer, in line with modernized regulatory approach from the U.S. Food and Drug Administration ● Announces partnership with Freenome to accelerate companion diagnostics development in immuno-oncology by combining industry-leading artificial intelligence with QIAGEN’s Sample to Insight solutions ● Showcases QIAGEN’s NGS technologies, including... Read more
Germantown, Maryland, and Hilden, Germany, May 23, 2018 – QIAGEN today announced the worldwide launch of the new DNeasy PowerSoil Pro Kit, the next generation of sample technology for the extraction of fungal and bacterial DNA from a range of soil samples. The new DNeasy PowerSoil Pro Kits featuring a streamlined version of QIAGEN’s proprietary... Read more
Employing next-generation Inhibitor Removal Technology and improved sample disruption, the kit boosts the well-known performance of PowerSoil kits in isolating microbial DNA from soils Germantown, Maryland, and Hilden, Germany, May 23, 2018 – QIAGEN today announced the worldwide launch of the new DNeasy PowerSoil Pro Kit, the next generation of sample technology for the extraction of fungal... Read more
The World Health Organization recommends IGRA tests in the First Edition of Essential In Vitro Diagnostics Germantown, Maryland, and Hilden, Germany, May 22, 2018 – QIAGEN today welcomed the First Edition of the World Health Organization’s (WHO) Essential Diagnostics List, which endorses the use of interferon gamma release assays (IGRAs) for the diagnosis of latent TB... Read more
Germantown, Maryland, and Hilden, Germany, May 22, 2018 – QIAGEN today welcomed the First Edition of the World Health Organization’s (WHO) Essential Diagnostics List, which endorses the use of interferon gamma release assays (IGRAs) for the diagnosis of latent TB infection. The inclusion on the list comes as the WHO and other organizations like the... Read more
MAY 15 2018 QIAGEN N.V. announces that it will initiate the repurchase of a first tranche of shares under the share repurchase program which was announced by an ad hoc announcement dated January 31, 2018. In the time period between May 15, 2018 until August 20, 2018, at the latest, a first tranche of up... Read more
Net sales of $343.6 million (+12% actual, +6% CER) vs. 5% CER guidance EPS $0.14; adjusted EPS $0.26 ($0.25 CER) vs. ~$0.23-0.24 CER guidance Sample to Insight portfolio building momentum: QIAstat-Dx, a next-generation platform offering syndromic insights for a broad range of applications, launched in Europe QuantiFERON latent TB test growth fueled by geographic expansion... Read more
Solid Q4 results as QIAGEN achieves full-year 2017 targets: Q4 2017: Net sales $396.9 million ( 8% actual, 5% CER); adjusted net sales rise 6% CER excluding portfolio changes vs. 5-6% CER guidance Q4 2017: EPS -$0.18 including impact of predominantly non-cash U.S. tax reform charge; adjusted EPS $0.43 ($0.43 CER) vs. ~$0.41-42 CER guidance... Read more
Germantown, Maryland, and Hilden, Germany, April 20, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory approval of PartoSure®, which is a novel test for assessing the risk of spontaneous preterm birth in patients with symptoms of preterm labor. The pre-market approval of PartoSure by the U.S. Food and... Read more